CoLucid Pharmaceuticals (CLCD) to Offer Common Shares
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, today announced that it intends to offer and sell shares of its common stock. CoLucid also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering on the same terms and conditions. All of the shares of the common stock to be sold in the proposed offering will be sold by CoLucid.
Piper Jaffray & Co. and Barclays Capital Inc. are acting as joint book-running managers for the proposed offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CRISPR Therapeutics AG (CRSP) IPO Opens Up 7%
- Nektar Therapeutics (NKTR) Prices 13M Common Stock Offering at $13.50/Share
- Fossil (FOSL): Swiss Watch Exports Fall 6% in September - Piper Jaffray
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesPiper Jaffray, Barclays
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!